Clinical trials
Oropharyngeal Squamous Cell Carcinoma clinical trials
Below are recruiting oropharyngeal squamous cell carcinoma clinical trials, each written for real people, not researchers. We’re tracking 127 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05799144RecruitingPhase 2
Pembrolizumab plus investigational HPV drugs for throat cancer
This Phase 2 trial studies pembrolizumab (an immune therapy) combined with investigational treatment(s) pBI-11 and TA-HPV for advanced or recurrent oropharyngeal cancer that is HPV-positive and has certain immune marker levels (PD-L1 CPS ≥ 1). It may help your immune system better attack cancer.
Birmingham, AlabamaAges 18 years+ - NCT03875716Recruiting
De-intensified radiation after surgery for HPV throat cancer
This trial studies a lower-intensity (less aggressive) course of radiation therapy after curative surgery for HPV-related tonsil or base-of-tongue cancer. The goal is to see if patients can still be treated successfully while reducing side effects from radiation.
Boston, MassachusettsAges 18 years+ - NCT04220749RecruitingPhase 2
Radiation vs mouth surgery for HPV-negative throat cancer
This Phase 2 trial compares two standard cancer treatments—radiation or surgery through the mouth—for HPV-negative oropharyngeal throat cancer. It aims to find out which approach works better while keeping side effects and quality of life acceptable.
London, OntarioAges 18 years+ - NCT04429542RecruitingPhase 1
Test of an EGFR-targeting drug for advanced solid cancers
This Phase 1 study tests the safety of BCA101 (an EGFR-targeting treatment) alone or combined with pembrolizumab. It may help people with certain EGFR-driven advanced cancers, depending on the tumor type, prior treatments, and required biopsy testing.
La Jolla, CaliforniaAges 18 years+ - NCT04444869RecruitingPhase 2
Lower-dose radiation with chemotherapy for low-risk HPV throat cancer
This trial tests whether a less intense (lower-dose) radiation plan, combined with chemotherapy, can control HPV-positive oropharyngeal (throat) cancer with fewer side effects. It targets people considered “low-risk” based on tumor size and lymph node involvement.
Columbia, MissouriAges 18 years+ - NCT04564989Recruiting
Biomarker study for HPV-related throat cancer outcomes
This observational study checks how well a blood test for HPV DNA (and other tumor genetic markers) predicts outcomes in certain throat cancers. It may help doctors better track the disease and plan treatment, because the trial validates these lab signals against real-world results.
Rochester, MinnesotaAges 18 years+ - NCT04671667RecruitingPhase 2
Pembrolizumab vs chemo-radiation after surgery for recurrent head/neck cancer
This trial tests whether pembrolizumab (an immunotherapy drug) works better than the usual chemo plus radiation after surgery for cancer that has come back in the head and neck area. It may help reduce cancer returning or spreading by using your immune system, but eligibility depends on how the cancer came back and your prior treatments.
Birmingham, AlabamaAges 18–79 - NCT04852328RecruitingPhase 2
Testing CUE-101 schedules before treatment for HPV16 throat cancer
This Phase 2 trial studies different timing “schedules” of CUE-101 given before surgery or before chemoradiation for HPV16-positive oropharyngeal throat cancer. The goal is to see if CUE-101 can help the body respond better and potentially improve outcomes.
St Louis, MissouriAges 18 years+ - NCT04900623RecruitingPhase 2
Using HPV blood test to guide treatment for HPV throat cancer
This Phase 2 study tests a “risk-adapted” treatment plan for HPV-related throat cancer, using an HPV DNA blood test to help decide how treatment is done. If your baseline blood test shows detectable HPV DNA, the study may help tailor therapy to your risk and potentially improve outcomes while limiting unnecessary treatment.
Boston, MassachusettsAges 22 years+ - NCT05098119RecruitingPhase 2
Study drugs before surgery for mouth or throat cancer
This Phase 2 trial tests giving the immunotherapy drug sintilimab before surgery, along with fewer chemotherapy cycles. The goal is to shrink or control oral or throat squamous cell cancers while keeping side effects lower, before the tumor is removed.
Guangzhou, GuangdongAges 18–80 - NCT05268614RecruitingPhase 2
Risk-based reduced chemo and radiation for HPV throat cancer
This trial tests whether using a lower intensity (reduced) chemo-radiation plan can work for some people with HPV-related oropharyngeal (throat) cancer without losing effectiveness. It may help reduce side effects while still controlling the cancer.
Gainesville, FloridaAges 18 years+ - NCT05307939RecruitingPhase 2
Using tumor DNA tests to time treatment for HPV throat cancer
This study checks a blood test that looks for HPV tumor DNA to help doctors decide when to start routine treatment after surgery. It may help some people avoid starting treatment too early or too late based on how the test changes after the operation.
Miami, FloridaAges 18 years+ - NCT05333523RecruitingPhase 3
Personalized neck radiation using a lymph node sentinel biopsy
This Phase 3 trial tests whether guiding neck radiation by checking the “sentinel” lymph node can target treatment more precisely in certain larynx, hypopharynx, or oropharynx cancers. It aims to improve control while potentially reducing unnecessary radiation to areas that don’t need it.
AmsterdamAges 18 years+ - NCT05522881Recruiting
Study of genetic changes in oropharyngeal cancer tumors
This study collects information and tumor tissue to look for genetic changes in oropharyngeal cancer, especially in patients whose cancer has come back. The goal is to better understand the disease and may help future treatment planning.
Kaohsiung CityAges 20 years+ - NCT05539638Recruiting
Testing blood DNA for head and neck squamous cancer
This study looks at how tumor DNA found in a blood sample (a “DNA signal”) relates to head and neck cancer in the oropharynx. It may help doctors understand disease status and improve how they monitor treatment, for both HPV-positive and HPV-negative cancers.
Dundee, DD2 1SGAges 18 years+ - NCT05541016RecruitingPhase 2
Personalized lower-dose radiation for HPV-related throat cancer
This Phase 2 study tests whether giving a less intense (de-escalated) radiation plan can work for certain people with HPV-related oropharyngeal throat cancer. It uses HPV blood testing and scans to help guide treatment, aiming to keep cancer control while reducing treatment side effects.
Scottsdale, ArizonaAges 18 years+ - NCT05582122RecruitingPhase 2
Tracking HPV16 DNA in blood to spot cancer coming back
This study checks whether a blood test for HPV16 DNA can predict when HPV-related throat cancer comes back after treatment. It may help improve follow-up care by catching recurrence earlier.
Saint-Denis, La RéunionAges 18 years+ - NCT05639972RecruitingPhase 1/Phase 2
HPV cancer trial using immune T cells made for you
This Phase 1/2 trial tests a one-time infusion of special immune T cells made to recognize your HPV16 tumor. It may help your body attack the cancer, while researchers closely monitor safety and early effectiveness.
New Brunswick, New JerseyAges 18 years+ - NCT05686226RecruitingPhase 2
Trial tests immune cells targeting HPV-16 cancers
This Phase 2 trial tests an immune-cell treatment (E7 TCR T cells) designed to attack cancers caused by HPV type 16. It may help people whose HPV-16+ cancer has come back or not responded to standard treatment.
Bethesda, MarylandAges 18 years+ - NCT05726370RecruitingPhase 2
Pembrolizumab plus chemo before surgery for recurrent head and neck cancer
This Phase 2 trial tests whether giving pembrolizumab (an immune therapy) plus chemotherapy before curative surgery can improve outcomes for people with resectable, recurrent head and neck squamous cell cancer. It also studies how these treatments affect the tumor and immune response using required tissue and blood samples.
Boston, MassachusettsAges 18 years+ - NCT05894083RecruitingPhase 2
PET-Scan Tailored De-escalation for p16+ throat cancer
This trial tests a treatment plan that may lower (de-escalate) therapy intensity for certain p16+ or HPV-positive throat cancers. It uses PET scan results and tumor features to try to keep cancer control while reducing side effects.
Ann Arbor, MichiganAges 18 years+ - NCT05962242RecruitingPhase 2
HPV-tested de-escalated radiation for HPV-related throat cancer
This Phase 2 study uses HPV test results from your tumor to safely lower (de-intensify) the strength of radiation for some HPV-positive oropharyngeal throat cancers. It aims to reduce side effects while keeping cancer control effective.
Miami, FloridaAges 18 years+ - NCT06055868Recruiting
HIV, oral cancer, and health equity study
This study looks at the experiences of people living with HIV who also have oral or throat cancer. The goal is to understand health disparities and improve care.
San Francisco, CaliforniaAges 18 years+ - NCT06064877RecruitingPhase 3
Study of ficlatuzumab plus cetuximab for advanced head and neck cancer
This trial tests a combination of two drugs, ficlatuzumab and cetuximab, for people with recurrent or metastatic head and neck cancer that is HPV-negative and has not responded to prior immunotherapy and chemotherapy. It aims to see if this combination can help shrink tumors or slow the disease.
Gilbert, ArizonaAges 18 years+
Hear when a new Oropharyngeal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for oropharyngeal squamous cell carcinoma?
- Yes. Clin2 currently lists 127 recruiting oropharyngeal squamous cell carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a oropharyngeal squamous cell carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a oropharyngeal squamous cell carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- HPV Positive Oropharyngeal Squamous Cell Carcinoma
- Recurrent Oropharyngeal Squamous Cell Carcinoma
- Metastatic Oropharyngeal Squamous Cell Carcinoma
- Oropharyngeal Squamous Cell Carcinoma (SCC)
- Head and Neck Squamous Cell Carcinoma
- Esophageal Squamous Cell Carcinoma
- Squamous Cell Carcinoma
- Clear Cell Renal Cell Carcinoma
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.